In fact, in an accompanying manuscript, we demonstrate that DISE can be triggered in vivo to treat ovarian cancer in mouse xenografts by delivering CD95L-derived siRNAs using nanoparticles (Murmann et al., 2017). Here, FASLG is linked to ovarian cancer.